The rationale for the use of CsA during primary HIV infection was to decrease the heightened state of T cell activation observed in order to limit infection, and thus depletion, of CD4+ T lymphocytes, contributing to a better long-term preservation. The gene discussed is CD4; the disease is HIV infectious disease.